167 related articles for article (PubMed ID: 31584927)
1. Simultaneous Quantification of Free Adalimumab and Infliximab in Human Plasma Using a Target-Based Sample Purification and Liquid Chromatography-Tandem Mass Spectrometry.
El Amrani M; Bosman SM; Egas AC; Hack CE; Huitema ADR; van Maarseveen EM
Ther Drug Monit; 2019 Oct; 41(5):640-647. PubMed ID: 31584927
[TBL] [Abstract][Full Text] [Related]
2. Quantification of active infliximab in human serum with liquid chromatography-tandem mass spectrometry using a tumor necrosis factor alpha -based pre-analytical sample purification and a stable isotopic labeled infliximab bio-similar as internal standard: A target-based, sensitive and cost-effective method.
El Amrani M; van den Broek MP; Göbel C; van Maarseveen EM
J Chromatogr A; 2016 Jul; 1454():42-8. PubMed ID: 27264745
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous Quantification of Adalimumab and Infliximab in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry.
Jourdil JF; Némoz B; Gautier-Veyret E; Romero C; Stanke-Labesque F
Ther Drug Monit; 2018 Aug; 40(4):417-424. PubMed ID: 29608486
[TBL] [Abstract][Full Text] [Related]
4. Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry: towards a standardization of the methods?
Jourdil JF; Lebert D; Gautier-Veyret E; Lemaitre F; Bonaz B; Picard G; Tonini J; Stanke-Labesque F
Anal Bioanal Chem; 2017 Feb; 409(5):1195-1205. PubMed ID: 27826630
[TBL] [Abstract][Full Text] [Related]
5. A multiplex liquid chromatography tandem mass spectrometry method for the quantification of seven therapeutic monoclonal antibodies: Application for adalimumab therapeutic drug monitoring in patients with Crohn's disease.
Willeman T; Jourdil JF; Gautier-Veyret E; Bonaz B; Stanke-Labesque F
Anal Chim Acta; 2019 Aug; 1067():63-70. PubMed ID: 31047150
[TBL] [Abstract][Full Text] [Related]
6. Middle-up quantification of therapeutic monoclonal antibodies in human plasma with two dimensional liquid chromatography high resolution mass spectrometry: Adalimumab as a proof of principle.
Amrani ME; van der Elst KCM; Huitema ADR; van Luin M
J Chromatogr A; 2022 Feb; 1665():462840. PubMed ID: 35121176
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous quantification of rituximab and eculizumab in human plasma by liquid chromatography-tandem mass spectrometry and comparison with rituximab ELISA kits.
Truffot A; Jourdil JF; Seitz-Polski B; Malvezzi P; Brglez V; Stanke-Labesque F; Gautier-Veyret E
Clin Biochem; 2021 Jan; 87():60-66. PubMed ID: 33096054
[TBL] [Abstract][Full Text] [Related]
8. Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays.
Van Stappen T; Brouwers E; Tops S; Geukens N; Vermeire S; Declerck PJ; Gils A
Ther Drug Monit; 2015 Aug; 37(4):479-85. PubMed ID: 25525757
[TBL] [Abstract][Full Text] [Related]
9. Verification between Original and Biosimilar Therapeutic Antibody Infliximab Using nSMOL Coupled LC-MS Bioanalysis in Human Serum.
Iwamoto N; Yokoyama K; Takanashi M; Yonezawa A; Matsubara K; Shimada T
Curr Pharm Biotechnol; 2018; 19(6):495-505. PubMed ID: 29968534
[TBL] [Abstract][Full Text] [Related]
10. Quantification of infliximab and adalimumab in human plasma by a liquid chromatography tandem mass spectrometry kit and comparison with two ELISA methods.
Tron C; Lemaitre F; Bros P; Goulvestre C; Franck B; Mouton N; Bagnos S; Coriat R; Khoudour N; Lebert D; Blanchet B
Bioanalysis; 2022 Jun; 14(11):831-844. PubMed ID: 35735172
[No Abstract] [Full Text] [Related]
11. Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels.
Ogrič M; Žigon P; Drobne D; Štabuc B; Sodin-Semrl S; Čučnik S; Praprotnik S
Immunol Res; 2018 Dec; 66(6):726-736. PubMed ID: 30569379
[TBL] [Abstract][Full Text] [Related]
12. A generic sample preparation method for the multiplex analysis of seven therapeutic monoclonal antibodies in human plasma or serum with liquid chromatography-tandem mass spectrometry.
Amrani ME; Gerencser L; Huitema ADR; Hack CE; van Luin M; van der Elst KCM
J Chromatogr A; 2021 Oct; 1655():462489. PubMed ID: 34509691
[TBL] [Abstract][Full Text] [Related]
13. Development of Label-Free Immunoassays as Novel Solutions for the Measurement of Monoclonal Antibody Drugs and Antidrug Antibodies.
Luo YR; Chakraborty I; Lazar-Molnar E; Wu AHB; Lynch KL
Clin Chem; 2020 Oct; 66(10):1319-1328. PubMed ID: 32918468
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Quantum Blue® reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels.
Novakovic V; Abdija S; Larsen PB; Fenger M; Gredal L; Jacobsen KK
Clin Biochem; 2019 Dec; 74():73-75. PubMed ID: 31669514
[TBL] [Abstract][Full Text] [Related]
15. Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison.
Valor L; Hernández-Flórez D; de la Torre I; Llinares F; Rosas J; Yagüe J; Garrido J; Naredo E
Clin Exp Rheumatol; 2015; 33(5):617-23. PubMed ID: 26316061
[TBL] [Abstract][Full Text] [Related]
16. Quantification of coagulation factor VIII in human plasma with liquid chromatography tandem mass spectrometry using a selective sample purification with camelid nanobodies.
El Amrani M; Donners AAM; Graat G; Lentjes EG; Huisman A; Musson REA; van Maarseveen EM
J Pharm Biomed Anal; 2019 Oct; 175():112781. PubMed ID: 31398627
[TBL] [Abstract][Full Text] [Related]
17. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
[TBL] [Abstract][Full Text] [Related]
18. Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays.
Afonso J; Lopes S; Gonçalves R; Caldeira P; Lago P; Tavares de Sousa H; Ramos J; Gonçalves AR; Ministro P; Rosa I; Vieira AI; Dias CC; Magro F;
Aliment Pharmacol Ther; 2016 Oct; 44(7):684-92. PubMed ID: 27507790
[TBL] [Abstract][Full Text] [Related]
19. Inductively coupled plasma mass spectrometry assay for quantification of free infliximab in serum.
Pavlov IY; Parker RL; Lázár-Molnár E; Strathmann FG; Delgado JC
J Immunol Methods; 2019 Jul; 470():33-39. PubMed ID: 31034880
[TBL] [Abstract][Full Text] [Related]
20. Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®.
Marini JC; Sendecki J; Cornillie F; Popp JW; Black S; Blank M; Gils A; Van Stappen T; Hamann D; Rispens T; Thérien L; Chun K; Shankar G
AAPS J; 2017 Jan; 19(1):161-171. PubMed ID: 27600137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]